Global Patent Prosecution Newsletter - December 2017

Global Patent Prosecution

A U.S. Perspective on Global Strategy

Worldwide Bolar Exemptions

Many countries have exemptions for patent infringement for a product and/or process that is not being used for direct commercialization and profit. For biopharmaceuticals, this exemption, commonly known as a “Bolar exemption”, permits activities with a commercial benefit as long as the activities are reasonably related to obtaining information relevant to a submission for regulatory approval. The December 2017 issue of Sterne Kessler’s Global Patent Prosecution Newsletter includes information on Bolar exemptions worldwide.

In this issue:

To read the full newsletter, please click the download button.

498.51 KB